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TLR2 plays a key role in innate immune response recognizing molecular patterns expressed by 28	
pathogens. rs111200466 is a TLR2 promoter Insertion/Deletion polymorphism with 29	
contradictory data about its role in HIV-1 infection. We analyzed rs111200466 in HIV-1 disease 30	
progression and showed a correlation with a faster progression to the CD4+<200cells/µL 31	
outcome for Deletion allele carriers (Cox regression analysis: Hazard Ratio=2.4; 95%CI:1.4-4, 32	
P=0.001). When naïve patients with CD4+<200cells/µL start antiretroviral treatment, 33	
rs111200466-Deletion carriers showed a trend towards a slower, recovery rate (time required to 34	
reach CD4+>350cells/µL, Cox P=0.36). Our data suggests rs111200466 as a prognosis factor 35	
for HIV-1 disease progression. 36	
 37	




Genetic differences in immune responses can be explained by the polymorphic nature of 40	
immune system genes. The ability of the immune system to distinguish pathogens is prompted 41	
via their binding to a family of pathogen recognition receptors (PRRs). Since their discovery, 42	
the focus has been on the recognition of pathogen-associated molecular patterns (PAMPs) that 43	
trigger innate immunity and enhance the adaptive immune response. The functions of several 44	
different classes of PRRs have been identified. In particular, Toll-like receptors (TLRs) family 45	
comprised by 10 genes that encode non-catalytic membrane receptors is the most characterized. 46	
A number of viral proteins have been identified as PAMPs for TLR2. Specific HIV structural 47	
proteins such as p17, p24, and gp41 interact with TLR2 leading to NFκB activation and the 48	
production of proinflammatory cytokines [1]. The primary consequence of viral recognition to 49	
the immune system is the production of proinflammatory cytokines and the subsequent 50	
recruitment of additional target cells. However, virally induced TLR2-dependent cellular 51	
activation has been shown to contribute to viral spread and pathogenesis due to enhanced 52	
expression of various viral entry receptors [2], thereby increasing viral infection [1]. These 53	
unique viral-PAMP specific alterations in receptor expression suggest a novel mechanism by 54	
which viruses can manipulate innate sensing with specific viral proteins. Indeed, different 55	
authors reported a significant increase in CCR5 expression in macrophages exposed to HIV-1 56	
PAMPs that led to significantly increased in vitro cell-free R5-HIV infection [1]. Also, previous 57	
publications have shown that there is a TLR2-dependent increase in CCR5 expression on 58	
permissible cells, resulting in significantly increased HIV infection[3]. Taken together, these 59	
studies highlight the role of TLR2 as an important extracellular PRR for viral PAMP 60	
recognition, resulting in increased cellular activation and facilitating viral infection. Under this 61	
scenario, we proposed that TLR2 variants might compromise host immune response to HIV-1 62	
infection. One of the mostly studied variant of TLR2 comprises a proximal promoter deletion (-63	
196 to -174 or rs111200466) which has been associated to HIV-1 infection progression with 64	
controversial results [4,5].  Thus, the objective of this work was to explore the impact of TLR2 65	
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insertion/deletion polymorphism on the immune impairment progression, measured as CD4+ T-66	
cell count along the HIV-1 infection progression. To this end we designed a multicentric study 67	
where TLR2 rs111200466 was determined in series of HIV-1 infected subjects and correlated 68	




In this multicentric study samples from 3 different series of HIV-infected individuals were 73	
analysed. The Malaga series was comprised by patients recruited between 2011 and 2013 at the 74	
Regional University Hospital of Malaga (Spain). The Lleida prospective cohort is comprised by 75	
HIV-1–seroprevalent injection drug users recruited between 1982 and 1991 from the AIDS 76	
Service of the Hospital Arnau de Vilanova of Lleida (Spain). These patients had been followed 77	
for a median of 127.7 months (interquartile range: 84–198) [6,7]. The Valme series was 78	
comprised by HIV-seroprevalent individuals who attended the Hospital Universitario de Valme, 79	
Seville (Spain). Clinical data from patients with available DNA were retrospectively digitalized. 80	
Valme series recruitment started in 1999 with a median follow-up of 59.5 months (interquartile 81	
range: 18–135). Antiretroviral therapy was provided according to the standardized medical 82	
guidelines in force at the moment of the visit in each hospital (Supplementary Table 1). This 83	
study was in compliance with the national legislation and it was performed according to the 84	
ethical guidelines of the Declaration of Helsinki. The Hospital Arnau de Vilanova Ethic’s 85	
committee approved the study for the Lleida cohort while the Malaga’s Hospital Carlos Haya 86	
committee did it for the Valme and Malaga series. Informed consent was obtained from all 87	






Statistical analyses were performed with R (v3.6.0) and IBM SPSS 21 software (IBM 92	
corporation, NY, USA). Non-parametric tests were applied for the analysis of CD4+ T-cell 93	
counts after verifying a non-normal distribution using Shapiro-Wilk’s method in the Lleida 94	
(P=1.28e-07), Malaga (P=2.7e-03) and Valme (P=5.02e-08) series. Thus, distribution of CD4+ 95	
T-cell counts was evaluated according to TLR2 rs111200466 genotype for each series by means 96	
of Kruskal-Wallis test. A meta-analysis combining all patients was performed using random 97	
effects model with meta package in R environment.	HIV-1 disease progression was evaluated 98	
by Kaplan–Meier survival analysis. The first decrease in the CD4+ T-cell count below 99	
200cells/µL was considered the outcome for disease progression. Time to the outcome ranged 100	
from date of the first HIV-1–positive test to the outcome date or censoring date (defined as the 101	
last clinic examination date or the date of death, if not caused by HIV-1 infection). Differences 102	
in profiles of time to the outcome between groups were compared by the Cox regression 103	
analysis. Hazard ratios were estimated using a Cox proportional hazard model that was further 104	
adjusted for sex and CCR5Δ32 genotype when appropriate[6,7]. In the same line, recovery of 105	
naïve patients with CD4+<200 cells/µL from the Valme series (n=51) was evaluated by 106	
Kaplan–Meier survival analysis as the time to reach CD4+>350 cells/µL after treatment setup. 107	
Differences in recovery profiles between rs111200466 genotypes of naïve patients were 108	
compared by the Cox regression analysis. 109	
 110	
Results 111	
The Lleida, Valme and Malaga series were constituted by 151, 133 and 223 HIV-infected 112	
individuals (Supplementary Table 1). All of them were genotyped for the TLR2 rs111200466 113	
and CCR5Δ32 genetic variants. The genotype distribution fitted the Hardy-Weinberg 114	
equilibrium in all series (Supplementary Table 2).  115	
In a first approach, we retrospectively analyzed patient CD4+ T-cell count levels at the 116	
recruitment timepoint. We observed that CD4+ levels (median, Q1-Q3) were lower among the 117	
Del allele carriers in the Malaga (439.9, 336.6-583.7 vs 500.1, 347.1-678.4, P=0.21) and Lleida 118	
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series (286, 152-491.5 vs 385.5, 225.8-537.8, P=0.11) (Figure 1A, B), however the same trend 119	
was not found in the Valme series (307.5, 164-390.8 vs 254, 139.5-379.5, P=0.43) (Figure 1C). 120	
An overall analysis with data from all series combined showed significant lower CD4+ levels 121	
among the rs111200466 Del carriers (339, 196-510 vs 397.8, 240.3-605.5, P=0.02). However, 122	
these differences were lost when a meta-analysis using random effects model was performed in 123	
order to account for inter-population variability (P=0.16).  124	
CD4+ T-cell count evolution was analyzed in the Lleida cohort as an outcome of disease 125	
progression. Of the 151 HIV-1–positive patients, the CD4+ T-cell count during follow-up 126	
remained at >200cells/µL in 88 (58.3%). Figure 2A shows the corresponding Kaplan-Meier plot 127	
for disease progression in the Lleida series grouping patients according to genotype under a 128	
dominant model. Of mention, those patients harboring the Ins/Ins genotype exhibited a 129	
significantly slower progression rate (median time to the outcome 171.3 months) than those 130	
with the Del allele (median time to the outcome 105.3 months; Cox regression analysis Hazard 131	
Ratio (HR)= 2.1; 95% confidence interval (CI): 1.27-3.5; P=0.004 Figure 2A) that remained 132	
significant after adjusting Cox regression analysis by sex and CCR5Δ32 (HR=2.4; 95%CI: 1.4-133	
4; P=0.001). Moreover, this effect was independent of those observed for sex (P=0.4) and 134	
CCR5Δ32 genotype (P=0.07) (Supplementary Table 3). Next, we analyzed the CD4+ T-cell 135	
recovery of naïve patients with CD4+<200 cells/µL from the Valme series (n=51), measured as 136	
the time to reach CD4+>350 cells/µL after treatment setup. Although patients with the Ins/Ins 137	
genotype (n=38) reached the recovery goal ≈50% earlier than the Del carriers 138	
(average+standard error: 111+18.5 vs 207.8+53.9 weeks, respectively), no statistically 139	
significant differences were found (HR=0.67; 95%CI: 0.29-1.56; P=0.36) (Figure 2B, 140	
Supplementary Table 3). 141	
 142	
The role of rs111200466 polymorphism in the expression of TLR2 gene has been investigated 143	
through the GTEx portal (ReleaseV7, https://www.gtexportal.org/home/) [8]. TLR2 was found 144	
to be generally expressed along the different tissues (Supplementary Figure 1A). When 145	
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expression-quantitative trait locus (eQTL) analysis was performed, we observed that the Del 146	
allele correlated with a lower TLR2 expression (Supplementary Figure 1B). As an illustrative 147	
example is illustrated in Supplementary Figure 1C. Average expression of the Ins/Ins subjects is 148	
significantly higher (Normalized Effect Size= -0.72, P=4.2e-34). In the same line, 149	
polymorphisms in strong linkage disequilibrium with rs111200466 such as rs1898832, 150	
rs62323831 and rs17270673 have also been reported as eQTLs for TLR2 (Data not shown). 151	
 152	
Discussion 153	
In the present study we evaluated the role of TLR2 rs111200466 in HIV-1 infection progression. 154	
We conducted a survival analysis taking advantage of the longitudinal CD4+ T-cell count data 155	
available at the Lleida cohort. We evaluated profiles of HIV-positive patients according to 156	
rs111200466 variants using the first decrease in CD4+ T-cell count <200cells/µL as a primary 157	
outcome for progression. Patients harboring the rs111200466 deletion allele exhibited a more 158	
rapid progression. The significance was independent of the CCR5Δ32 genotype suggesting that 159	
the mechanism underlying disease progression might not involve virus entry. Next, although 160	
results were not statistically different, we observed at the Valme series that naïve patients with 161	
low CD4+ T-cell count and rs111200466 deletion allele showed a worse response to the 162	
antiretroviral treatment, and required nearly twice as much time to recover CD4+>350 cells/µL. 163	
All these data together seems to indicate that rs111200466 deletion might be compromising the 164	
immune response of the patients. 165	
TLR2 is expressed in sentinel cells, skin and epithelial cells such as the lung, and renal tubules 166	
and has the ability to act forming heterodimers with TLR1, 6 and 10 what further expands the 167	
number of PAMPs that it can interact with [9,10]. It has been also shown that TLR2 is 168	
overexpressed in monocytes from HIV-1 infected patients [11] and it has been postulated that 169	
the increase in TLR2 expression may favour HIV-1 cell-entry. TLR2 is found in different forms 170	
in the human body and their role in HIV-1 infection has been shown to be different. For 171	
example, some HIV-1 structural proteins act as PAMPS activating membrane bound TLR2 172	
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heterodimers and the subsequent pathways modulating NFκB or CCR5 expression, while others 173	
block TLR2 activation [1]. Our results, together with those from the eQTL analysis point out 174	
that a decrease of TLR2 expression mediated by the presence of the Del allele will have a risk 175	
effect on disease progression rates. We can only speculate to which extend TLR2 rs111200466 176	
deletion allele might compromise the production of proinflammatory cytokines and different 177	
transcription factors and could affect the sensing of different PAMPS. Previous studies 178	
evaluated the role of this polymorphism and the risk of HIV-1 infection with contradictory 179	
results [5,6]. Initially, Vidyant et al. proposed the TLR2 rs111200466 deletion as a susceptibility 180	
allele, however in a later study Royo et al. reported a Hardy-Weinberg disturbance in Vidyant`s 181	
data and found a protective effect of TLR2 rs111200466 deletion to HIV-1 infection. This is not 182	
the first polymorphism with a dual effect, affecting susceptibility and infection progression 183	
simultaneously[12,13]. TLR2 involved in the response of opportunistic pathogens such as 184	
tuberculosis, what is associated to NFκB activation and a higher HIV replication rate. This 185	
might explain the influence of TLR2 in both susceptibility and progression. Additional TLR2 186	
polymorphisms have been correlated with viral load with different results[14,15].  187	
We acknowledge a number of limitations in our study. First, evidence of CD4+ T-cell counts 188	
affected by TLR2 genotype is only described in HIV-1 infected patients and the role in healthy 189	
controls remains unclear. Survival analyses are significant in a unique cohort and will require 190	
replication. Second, the discrepancies in the initial CD4+ counts observed in the Valme series 191	
might reflect a differential time of infection prior to attending to the Hospital, what might be 192	
explained by prospective vs retrospective nature of the Lleida and Valme series. Finally, we 193	
should state that the Valme analysis was conditioned by the availability of DNA samples. Thus, 194	
a selection bias cannot be excluded. 195	
In conclusion, our results suggest a role of TLR2 in HIV-1 disease progression rates that may be 196	
independent of the effect of this gene in the susceptibility to infection. Our analysis together 197	
with GTEx data link lower levels of TLR2 and a diminished CD4+ T-cell counts and a worse 198	
prognosis, probably due to a lower activation of the immune. Altogether, these findings reveal 199	
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novel mechanisms of viral infection control that should be further studied to fully understand 200	
the complex regulatory network orchestrating immune response upon HIV-1 infection.  201	
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Figure 1. Boxplot depicting CD4+ T-cell counts distribution including the number of patients 265	
per group. Line depicts median CD4+ T-cell count, box lower and upper hinges correspond to 266	
the first and third quartiles, whiskers extend from the hinge to the largest or lower value (no 267	
further than 1.5 times the inter quartile range) and the numbers above each boxplot represent the 268	
number of individuals represented. 269	
 270	
Figure 2. Role of rs111200466 genotype on CD4+ level progression under the Del allele 271	
dominant model by means of Kaplan–Meier analysis. A) Lleida patients reaching the outcome 272	
of CD4+ T-cell count below 200 cells/µL for disease progression during follow-up. P-Value 273	
from adjusted Cox regression analysis, B) Time to recovery (time to CD4+ >350 cells/µL) of 274	
Valme naïve patients. P-Value from univariate Cox regression analysis.275	
 276	
 277	
